These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29620892)

  • 1. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
    Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
    J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
    Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Potent
    Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
    Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
    Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
    Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
    Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS
    Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
    Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
    Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
    Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
    Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
    Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
    Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for specific inhibition of Autotaxin by a DNA aptamer.
    Kato K; Ikeda H; Miyakawa S; Futakawa S; Nonaka Y; Fujiwara M; Okudaira S; Kano K; Aoki J; Morita J; Ishitani R; Nishimasu H; Nakamura Y; Nureki O
    Nat Struct Mol Biol; 2016 May; 23(5):395-401. PubMed ID: 27043297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.